El valor de la templanza en las relaciones familiares (En los escritos de Pedro-Juan Viladrich Bataller)

La familia “es una comunidad de personas, para las cuales el propio modo de existir y vivir juntos” exige la vivencia intensa y cotidiana del amor “bueno”, que es el “principio interior”, la “fuerza permanente” de las relaciones intrafamiliares, que son únicas y exclusivas de la “comunidad doméstica”, pues brotan de la “conyugalidad” y la “consanguinidad”. Los familiares para vivir bien estas relaciones amorosas cuentan con un conjunto de valores que les son propios e intrínsecos, entre cuales se encuentra el valor familiar de la templanza, que propicia un ambiente hogareño de armonía, estabilidad y unidad. Enseñando, adquiriendo y viviendo este valor los esposos, padres, hijos y hermanos avivan y renuevan la dinámica del “amor familiar incondicional y desnudo”: darse a sí mismo y abrirse para recibir al otro con todo lo que es y tiene.The family “is a community of persons, whose own way of existing and living together” requires a daily intense experience of “good” love, that is the inner principle, the permanent power of intra-family relationships, that are unique and exclusive of the “domestic community”, as they arise from the “conjugality” and the “consanguinity”. To live well these relationships of love the relatives have a group of values that are exclusive and inherent, among which, the temperance is one of the family values that fosters a homey atmosphere of harmony, stability, and unity. Teaching, acquiring and living this value, husbands and wives, fathers and mothers, sons and daughters, and brothers and sisters intensify and renew the dynamics of the “transparent and unconditional family love”; self-giving to oneself and opening to the other accepting what he is and he has

Monitoring Of Bcr-abl Levels In Chronic Myeloid Leukemia Patients Treated With Imatinib In The Chronic Phase - The Importance Of A Major Molecular Response

Background: Real time PCR has become the most common technique to monitor BCR-ABL transcript levels of patients treated with kinase inhibitors. The aim of this study was to evaluate BCR-ABL levels of chronic myeloid leukemia patients treated with imatinib in the chronic phase and correlate the response to therapy and event-free survival. Methods: BCR-ABL levels were measured in peripheral blood cell samples using Real time PCR at diagnosis and then every 3 months after starting therapy with imatinib. Major molecular response was defined as a three-log reduction from the standardized baseline value. Major molecular response values were adjusted to international scale using a conversion factor of 1.19. The results are reported as a BCR-ABL/ABL ratio (%). Results: Hematological, major cytogenetic and complete cytogenetic responses were achieved by 57 (95%), 45 (75%) and 38 (63%) patients, respectively. Twenty-four out of sixty patients achieved a major molecular response (40%) in a median time of 8.5 months. Overall survival and event free survival were higher for patients with (100%) versus patients without (77%) a complete cytogenetic response (p-value = 0.01) at 48 months. Patients with complete cytogenetic response and major molecular response had a higher event free survival compared to patients with complete cytogenetic response but without major molecular response (p-value = 0.007). Conclusion: In conclusion, the prognostic impact of achieving complete cytogenetic response and a major molecular response and also the importance of molecular monitoring in the follow-up of chronic myeloid leukemia patients were demonstrated.333211215Melo, J.V., The molecular biology of chronic myeloid leukaemia (1996) Leukemia, 10 (5), pp. 751-756Wang, L., Pearson, K., Pillitteri, L., Ferguson, J.E., Clark, R.E., Serial monitoring of BCR-ABL by peripheral blood real-time polymerase chain reaction predicts the marrow cytogenetic response to imatinib mesylate in chronic myeloid leukaemia (2002) Br J Haematol, 118 (3), pp. 771-777Muller, M.C., Gattermann, N., Lahaye, T., Deininger, M.W., Berndt, A., Fruehauf, S., Dynamics of BCR-ABL mRNA expression in firstline therapy of chronic myelogenous leukemia patients with imatinib or interferon alpha/ara-C (2003) Leukemia, 17 (12), pp. 2392-2400Branford, S., Hughes, T.P., Rudzki, Z., Monitoring chronic myeloid leukaemia therapy by real-time quantitative PCR in blood is a reliable alternative to bone marrow cytogenetics (1999) Br J Haematol, 107 (3), pp. 587-599Radich, J.P., Gooley, T., Bryant, E., Chauncey, T., Clift, R., Beppu, L., The significance of bcr-abl molecular detection in chronic myeloid leukemia patients late, 18 months or more after transplantation (2001) Blood, 98 (6), pp. 1701-1707Hughes, T.P., Kaeda, J., Branford, S., Rudzki, Z., Hochhaus, A., Hensley, M.L., Frequency of major molecular responses to imatinib or interferon-alpha plus cytarabine in newly diagnosed chronic myeloid leukemia (2003) N Engl J Med, 349 (15), pp. 1423-1432Press, R.D., Love, Z., Tronnes, A.A., Yang, R., Tran, T., Mongoue- tchokote, S., BCR-ABL mRNA levels at and after the time of a complete cytogenetic response predict the duration of CCR in imatinib mesylate-treated patients with CML (2006) Blood, 107 (11), pp. 4250-4256Cortes, J., Talpaz, M., O'Brien, S., Jones, D., Luthra, R., Shan, J., Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate (2005) Clin Cancer Res, 11 (9), pp. 3425-3432Iacobucci, I., Saglio, G., Rosti, G., Testoni, N., Pane, F., Amabile, M., Achieving a major molecular response at the time of a complete cytogenetic response (CCgR) predicts a better duration of CCgR in imatinib-treated chronic myeloid leukemia patients (2006) Clin Cancer Res, 12 (10), pp. 3037-3042Baccarani, M., Saglio, G., Goldman, J., Hochhaus, A., Simonsson, B., Appelbaum, F., Evolving concepts in the management of chronic myeloid leukemia: Recommendations from an expert panel on behalf of the European LeukemiaNet (2006) Blood, 108 (6), pp. 1809-1820Hughes, T., Deininger, M., Hochhaus, A., Branford, S., Radich, J., Kaeda, J., Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: Review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results (2006) Blood, 108 (1), pp. 28-37Branford, S., Cross, N.C., Hochhaus, A., Radich, J., Saglio, G., Kaeda, J., Rationale for the recommendations for harmonizing current methodology for detecting BCR-ABL transcripts in patients with chronic myeloid leukaemia (2006) Leukemia, 20 (11), pp. 1925-1930Cortes, J., Baccarani, M., Fea, G., (2008) A Phase III, Randomized, Openlabel Study of 400 Mg Versus 800 Mg of Imatinib Mesylate (IM) in Patients With Newly Diagnosed, Previously Untreated Chronic Myeloid Leukemia in Chronic Phase (CML-CP), Using Molecular Endpoints: One Year Results of TOPS (Tyrosine Kinase Inhibitor Optimization and Selectivity) Study, , 50th ASH Annual Meeting and Exposition Online program and Abstracts. San Francisco, CABranford, S., Fletcher, L., Cross, N.C., Muller, M.C., Hochhaus, A., Kim, D.W., Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials (2008) Blood, 112 (8), pp. 3330-3338O'Brien, S.G., Guilhot, F., Larson, R.A., Gathmann, I., Baccarani, M., Cervantes, F., Imatinib compared with interferon and lowdose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia (2003) N Engl J Med, 348 (11), pp. 994-1004Marin, D., Milojkovic, D., Olavarria, E., Khorashad, J.S., de Lavallade, H., Reid, A.G., European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor (2008) Blood, 112 (12), pp. 4437-444

Transfer-matrix scaling from disorder-averaged correlation lengths for diluted Ising systems

A transfer matrix scaling technique is developed for randomly diluted systems, and applied to the site-diluted Ising model on a square lattice in two dimensions. For each allowed disorder configuration between two adjacent columns, the contribution of the respective transfer matrix to the decay of correlations is considered only as far as the ratio of its two largest eigenvalues, allowing an economical calculation of a configuration-averaged correlation length. Standard phenomenological-renormalisation procedures are then used to analyse aspects of the phase boundary which are difficult to assess accurately by alternative methods. For magnetic site concentration $p$ close to $p_c$, the extent of exponential behaviour of the $T_c \times p$ curve is clearly seen for over two decades of variation of $p - p_c$. Close to the pure-system limit, the exactly-known reduced slope is reproduced to a very good approximation, though with non-monotonic convergence. The averaged correlation lengths are inserted into the exponent-amplitude relationship predicted by conformal invariance to hold at criticality. The resulting exponent $\eta$ remains near the pure value (1/4) for all intermediate concentrations until it crosses over to the percolation value at the threshold.Comment: RevTeX 3, 11 pages +5 figures, uuencoded, to appear in Phys. Rev. B (1994), PUC/RJ preprin

Implant of Port-o-Cath for antineoplastic chemotherapy in a canine: case report

O Port-o-Cath é um cateter venoso central totalmente implantável, o qual permite a infusão de quimioterápicos, hemoderivados, nutrição parenteral e coleta de sangue. Este trabalho relata o caso de um canino com um tumor no membro pélvico que foi tratado cirurgicamente e recebeu o cateter para a quimioterapia antineoplásica. A paciente possuía um sarcoma sinovial, tumor incomum em cães, que acomete normalmente as articulações e exige terapia multimodal. O tratamento foi feito em duas etapas; na primeira, o membro foi amputado e, na segunda, foi realizado o implante do Port-o-Cath e exérese de nódulo metastático. A cadela respondeu satisfatoriamente à cirurgia e realizou as sessões de quimioterapia com perfeito funcionamento do cateter, indo a óbito por outras causas 90 dias após o procedimento. O implante de Port-o-Cath para a quimioterapia é um grande aliado à terapia multimodal preconizada para o câncer, podendo o cateter ser considerado em pacientes que necessitem de medicação quimioterápica por longo período.The Port-a-Cath is a totally implantable central venous catheter that allows the infusion of chemotherapeutic agents, blood products, parenteral nutrition, and blood sample collection. This work reports the case of a dog with a tumor in the pelvic limb that was treated surgically and received the catheter for cancer chemotherapy. The patient was diagnosed with synovial sarcoma, an uncommon tumor in dogs that usually affects the joints and requires multimodal therapy. The treatment was done in two steps, in the first the limb was amputated and in the second the Port-a-Cath implantation and the excision of the metastatic nodule were performed. The dog responded well to surgery and chemotherapy sessions held with proper functioning of the catheter, and died from other causes 90 days after the procedure. The implantation of Port-a-Cath for chemotherapy is a great ally of multimodal therapy recommended for cancer, so this catheter may be considered for patients requiring chemotherapy medication for a long period

Co-infecção pelo vírus dengue 3 e 4 em pacientes da Amazônia brasileira

The natural co-infection with dengue virus can occur in highly endemic areas where different serotypes have been observed for many years. We report here four cases of DENV-3/DENV-4 co-infection detected by serological and molecular tests among 674 patients with acute undifferentiated fever from the tropical medicine reference center of Manaus City, Brazil, between 2005 and 2010. Analysis of the sequences obtained indicated the presence of genotype 3 and 1 for DENV-3 and DENV-4 respectively.A co-infecção natural com os vírus dengue pode ocorre em áreas altamente endêmicas onde diferentes sorotipos têm sido transmitidos por muitos anos. Relatamos aqui quatro casos de co-infecção com DENV-3/DENV-4 detectados por testes sorológicos e moleculares entre 674 pacientes com febre indiferenciada aguda, atendidos em um centro de medicina tropical de referência da cidade de Manaus, Brasil, entre 2005 e 2010. As análises das sequências obtidas indicaram a presença dos genotipos 3 e 1 para DENV-3 e DENV-4 respectivamente

Electron localization : band-by-band decomposition, and application to oxides

Using a plane wave pseudopotential approach to density functional theory we investigate the electron localization length in various oxides. For this purpose, we first set up a theory of the band-by-band decomposition of this quantity, more complex than the decomposition of the spontaneous polarization (a related concept), because of the interband coupling. We show its interpretation in terms of Wannier functions and clarify the effect of the pseudopotential approximation. We treat the case of different oxides: BaO, $\alpha$-PbO, BaTiO$_3$ and PbTiO$_3$. We also investigate the variation of the localization tensor during the ferroelectric phase transitions of BaTiO$_3$ as well as its relationship with the Born effective charges

Higher Order Evaluation of the Critical Temperature for Interacting Homogeneous Dilute Bose Gases

We use the nonperturbative linear \delta expansion method to evaluate analytically the coefficients c_1 and c_2^{\prime \prime} which appear in the expansion for the transition temperature for a dilute, homogeneous, three dimensional Bose gas given by T_c= T_0 \{1 + c_1 a n^{1/3} + [ c_2^{\prime} \ln(a n^{1/3}) +c_2^{\prime \prime} ] a^2 n^{2/3} + {\cal O} (a^3 n)\}, where T_0 is the result for an ideal gas, a is the s-wave scattering length and n is the number density. In a previous work the same method has been used to evaluate c_1 to order-\delta^2 with the result c_1= 3.06. Here, we push the calculation to the next two orders obtaining c_1=2.45 at order-\delta^3 and c_1=1.48 at order-\delta^4. Analysing the topology of the graphs involved we discuss how our results relate to other nonperturbative analytical methods such as the self-consistent resummation and the 1/N approximations. At the same orders we obtain c_2^{\prime\prime}=101.4, c_2^{\prime \prime}=98.2 and c_2^{\prime \prime}=82.9. Our analytical results seem to support the recent Monte Carlo estimates c_1=1.32 \pm 0.02 and c_2^{\prime \prime}= 75.7 \pm 0.4.Comment: 29 pages, 3 eps figures. Minor changes, one reference added. Version in press Physical Review A (2002